What are ADC's

Our services

ADC Review
is made possible by:

NCT01891669 (Clinical Trial / PF-06263507)

Study Title
A Study Of PF-06263507 In Patients With Advanced Solid Tumors (NCT01891669)

Trial Description
To assess the safety and tolerability at increasing dose levels of PF-06263507 (A1-mcmMMAF / anti-5T4 monoclonal antibody) in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase II dose.

This trial is sponsored by Pfitzer, Inc [1]

Study Data

  • Condition:
    • Neoplasms
    • Non Small Cell Lung Carcinoma
    • Breast Neoplasms
    • Ovarian Neoplasms
  • Interventions:
    • Drugs used in this trial
      • PF-06263507
  • Phase: I
  • Estimated Enrollment: 36
  • Start: August 2013
  • Estimated Completion: November 2016
  • Last verified: July 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 10, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar